{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=71&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Phoenix",
      "page": 71
    },
    "page_size": 10
  },
  "pagination": {
    "page": 71,
    "page_size": 10,
    "total_count": 8148,
    "total_pages": 815,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=72&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Phoenix&page=70&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T18:09:08.452Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02829814",
      "title": "Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia",
        "Myofascial Pain Syndromes",
        "Muscular Diseases",
        "Nervous System Diseases",
        "Neuromuscular Diseases",
        "Rheumatic Diseases",
        "Musculoskeletal Diseases"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL Tablet, 2.8 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo SL Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2016-07-22",
      "completion_date": "2016-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829814"
    },
    {
      "nct_id": "NCT01374906",
      "title": "Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cushing's Disease"
      ],
      "interventions": [
        {
          "name": "pasireotide LAR",
          "type": "DRUG"
        },
        {
          "name": "SOM230 LAR 30 mg",
          "type": "DRUG"
        },
        {
          "name": "SOM230 LAR 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2011-11-04",
      "completion_date": "2016-12-21",
      "has_results": true,
      "last_update_posted_date": "2018-05-22",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01374906"
    },
    {
      "nct_id": "NCT03767348",
      "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Microsatellite Instability-High (MSI-H)",
        "Non-melanoma Skin Cancer (NMSC)",
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "RP1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2017-09-20",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03767348"
    },
    {
      "nct_id": "NCT01436500",
      "title": "Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatorenal Syndrome"
      ],
      "interventions": [
        {
          "name": "Ifetroban Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2011-10",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436500"
    },
    {
      "nct_id": "NCT00810264",
      "title": "Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "CRT Therapy - LV Lead Registry",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Biotronik, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2499,
      "start_date": "2008-12",
      "completion_date": "2018-11-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 83 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00810264"
    },
    {
      "nct_id": "NCT06807099",
      "title": "WRAP North America",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Stenosis",
        "Venous Occlusion"
      ],
      "interventions": [
        {
          "name": "Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Merit Medical Systems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2025-07-31",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 14,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Riverside, California + 11 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06807099"
    },
    {
      "nct_id": "NCT03436199",
      "title": "Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Walking Impairment",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ADS-5102, 137 mg",
          "type": "DRUG"
        },
        {
          "name": "ADS-5102, 274 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Adamas Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 558,
      "start_date": "2018-03-29",
      "completion_date": "2019-12-10",
      "has_results": true,
      "last_update_posted_date": "2021-12-21",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 78,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03436199"
    },
    {
      "nct_id": "NCT03701763",
      "title": "Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Apremilast (CC-10004)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 245,
      "start_date": "2018-12-19",
      "completion_date": "2023-03-27",
      "has_results": true,
      "last_update_posted_date": "2024-12-16",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701763"
    },
    {
      "nct_id": "NCT04333147",
      "title": "Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "Otilimab (GSK3196165)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "csDMARD(s)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2916,
      "start_date": "2020-05-12",
      "completion_date": "2023-02-24",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 79,
      "location_summary": "Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04333147"
    },
    {
      "nct_id": "NCT00767949",
      "title": "Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "iSONEP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lpath, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-10",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-04-16",
      "last_synced_at": "2026-10-25T18:09:08.452Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00767949"
    }
  ]
}